Advisory Alpha’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Advisory Alpha’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-12,005	Closed	-$22.2K	–	342
2023 Q1	$22.2K	Hold	12,005	–	–	﹤0.01%	279
2022 Q4	$13.3K	Hold	12,005	–	–	﹤0.01%	260
2022 Q3	$28K	Hold	12,005	–	–	﹤0.01%	239
2022 Q2	$36K	Hold	12,005	–	–	﹤0.01%	245
2022 Q1	$82K	Hold	12,005	–	–	0.01%	264
2021 Q4	$100K	Hold	12,005	–	–	0.01%	258
2021 Q3	$89K	Hold	12,005	–	–	0.01%	237
2021 Q2	$82K	Buy	+12,005	New	+$99.7K	0.01%	188

Other funds holding JNCE

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Advisory Alpha's JNCE Position: Q2 2023 in Review

Advisory Alpha sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 12,005 shares — an estimated $22.2K sold.

Advisory Alpha first reported a position in JNCE in Q2 2021 and held it in 8 quarters. The position peaked at $100K in Q4 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

Advisory Alpha reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Advisory Alpha sold 12,005 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $22.2K.
Advisory Alpha first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
Advisory Alpha's Jounce Therapeutics, Inc. Common Stock position peaked at $100K in Q4 2021.
1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Advisory Alpha's 13F filing for Q2 2023, filed 25 Jul 2023.